DDInter1088 DDInter1658
Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Loperamide {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextropropoxyphene
Loperamide {u} (Compound) resembles {v} (Compound) Clofedanol
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
Loperamide {u} (Compound) upregulates {v} (Gene) SQLE
Loperamide {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Agonists
Loperamide {u} (Compound) downregulates {v} (Gene) MRPL12
Loperamide {u} (Compound) causes {v} (Side Effect) Nausea
Loperamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholestyramine
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Loperamide (Compound) resembles Methadyl Acetate (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene
Loperamide (Compound) resembles Clofedanol (Compound)
Loperamide (Compound) binds CYP3A4 (Gene)
Loperamide (Compound) upregulates SQLE (Gene)
Loperamide (Compound) is included by Opioid Agonists (Pharmacologic Class)
Loperamide (Compound) downregulates MRPL12 (Gene)
Loperamide (Compound) causes Nausea (Side Effect)
Loperamide may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor